Gestational Diabetes Mellitus – An Update on Screening, Diagnosis, and Follow-up

Objectives

Strengthen the detection, diagnosis, management and long-term follow-up of diabetes in pregnancy in Singapore, encompassing pre-existing diabetes, pre-diabetes and gestational diabetes mellitus (GDM). The overall aim is to improve maternal and neonatal outcomes through early identification and timely treatment, including lifestyle measures, dietary advice, exercise and insulin where needed.[1][2]

• Identify previously undiagnosed pre-existing diabetes in women at higher risk before conception or at the first prenatal visit.[1][3]
• Screen women without diagnosed diabetes or pre-diabetes for GDM at 24 to 28 weeks of pregnancy.[1][3]
• Use pregnancy-appropriate oral glucose tolerance testing rather than glycated haemoglobin (HbA1c), which is considered unsuitable for screening or diagnosis during pregnancy because of reduced sensitivity to postprandial hyperglycaemia, lower values in pregnancy and a lack of local validation.[2]
• Apply the International Association of Diabetes and Pregnancy Study Groups criteria through a 75 g, three-point oral glucose tolerance test: diagnose GDM where any one value meets the threshold of fasting plasma glucose of at least 5.1 mmol/L, one-hour glucose of at least 10.0 mmol/L, or two-hour glucose of at least 8.5 mmol/L.[3][4]
• Provide timely management and healthy-lifestyle support to women diagnosed with diabetes during pregnancy, while applying tighter glycaemic control and complication screening, including eye assessment, for women with pre-existing diabetes.[3][2]
• Reduce later progression to type 2 diabetes mellitus through post-delivery surveillance and lifestyle intervention, particularly for women with prior GDM. Lifestyle intervention is associated with a 35% reduction in progression over 10 years.[2]

The long-term prevention focus reflects substantial subsequent risk: women with a history of GDM are reported to be around 10 times more likely to develop type 2 diabetes mellitus than women with a normoglycaemic pregnancy, and an estimated four in 10 women in Singapore develop type 2 diabetes mellitus or pre-diabetes within four to six years after delivery.[2]

Implementation

Deliver care through a structured antenatal-to-postnatal pathway that combines risk-based early testing for pre-existing diabetes, universal GDM screening at 24 to 28 weeks, differentiated management according to glycaemic status, and continuing diabetes prevention follow-up after delivery. The guidance was developed through Singapore’s Agency for Care Effectiveness, a Ministry of Health body supporting healthcare decision-making through health technology assessment, healthcare guidance and education, with input from an expert group drawn from major healthcare institutions.[3][5][4]

• Assess women at increased risk of pre-existing diabetes before conception or at the first antenatal visit using non-pregnancy glucose thresholds, and re-test women with normal early results for GDM at 24 to 28 weeks. Relevant risk factors include a pre-pregnancy body mass index of at least 23 kg/m², previous GDM, previous delivery of a baby weighing at least 4 kg, polycystic ovary syndrome, pre-diabetes, age of at least 40 years, a first-degree family history of diabetes and hypertension.[1][3]
• Offer universal three-point 75 g oral glucose tolerance testing at 24 to 28 weeks to women without known diabetes or pre-diabetes, rather than relying solely on risk-based screening. This approach reflects the higher prevalence of GDM in Asian populations and reported benefits of universal screening.[3]
• Confirm results above a diagnostic threshold by repeating the relevant test.[2][4]
• Refer women diagnosed with diabetes to specialist diabetes management and diabetes-complication screening.[4]
• Initiate lifestyle intervention and glucose monitoring for pre-diabetes, and consider pharmacotherapy where lifestyle intervention does not consistently achieve glycaemic control.[4]
• Reassess women whose diabetes was diagnosed during pregnancy at six to 12 weeks after delivery using a fasting and two-hour, 75 g oral glucose tolerance test with non-pregnancy thresholds.[1][2]
• Classify post-pregnancy diabetes at fasting plasma glucose of at least 7.0 mmol/L or two-hour glucose of at least 11.1 mmol/L; classify pre-diabetes at fasting plasma glucose of 6.1 to 6.9 mmol/L or two-hour glucose of 7.8 to 11.0 mmol/L.[4]
• Repeat diabetes screening every one to three years after a normal initial post-delivery result, ideally annually, and consider more frequent monitoring for women who required insulin in pregnancy or have additional risk factors such as body mass index of at least 23 kg/m² or a family history of diabetes.[1][2]

The named professional and clinical contributors include the Academy of Medicine, Singapore; its Chapter of Endocrinologists; the Chapter of Family Medicine Physicians; the College of Obstetricians and Gynaecologists, Singapore; and experts from KK Women’s and Children’s Hospital, National University Health System, Singapore General Hospital, Tan Tock Seng Hospital and Khoo Teck Puat Hospital.[1][4]The Appropriate Care Guide is intended for review around five years after publication, or earlier if new evidence requires substantive recommendation changes.[5]

The material provides diagnostic thresholds, testing intervals and clinical follow-up actions, but does not specify broader reporting systems, performance indicators, accountability arrangements, implementation budgets, financing mechanisms or resource requirements.[1][3][2][4][5]

Monitoring & Evaluation

Monitoring centres on structured glucose testing during and after pregnancy, with defined diagnostic thresholds, repeat testing where results are abnormal, and long-term surveillance for women with diabetes diagnosed during pregnancy.[1][2][4]The guidance also provides for periodic review of the Appropriate Care Guide, but does not establish a wider reporting, performance-management or accountability framework.[2][4][5]

• Assess women at increased risk of pre-existing diabetes before conception or at their first prenatal visit using non-pregnancy glucose thresholds, then re-evaluate those with normal results for gestational diabetes mellitus (GDM) at 24 to 28 weeks.[3]
• Screen women without diagnosed diabetes or pre-diabetes for GDM at 24 to 28 weeks using a three-point 75 g oral glucose tolerance test.[3][4]
• Diagnose GDM when any one of the International Association of Diabetes and Pregnancy Study Groups thresholds is met: fasting plasma glucose of at least 5.1 mmol/L, one-hour glucose of at least 10.0 mmol/L, or two-hour glucose of at least 8.5 mmol/L.[3][4]
• Avoid using glycated haemoglobin to screen for or diagnose diabetes during pregnancy, because it is less sensitive to postprandial hyperglycaemia, is generally lower in pregnancy, and has not been locally validated for this use.[2]
• Confirm results above a diagnostic threshold by repeating the relevant test.[2][4]
• Reassess women whose diabetes was diagnosed during pregnancy at six to 12 weeks after delivery using a two-point, fasting and two-hour, 75 g oral glucose tolerance test and non-pregnancy thresholds.[1][2]
• Classify post-pregnancy diabetes as fasting plasma glucose of at least 7.0 mmol/L or a two-hour value of at least 11.1 mmol/L.[4]Classify pre-diabetes as fasting plasma glucose of 6.1 to 6.9 mmol/L or a two-hour value of 7.8 to 11.0 mmol/L.[4]
• Continue diabetes screening every one to three years after a normal initial post-delivery result, ideally annually.[1][2][4]Consider more frequent follow-up for women who required insulin during pregnancy or who have additional risk factors, including non-pregnancy body mass index of at least 23 kg/m² or a family history of diabetes.[2]
• Use continuing surveillance to address the elevated later-life diabetes risk after GDM: women with previous GDM are reported to be about 10 times more likely to develop type 2 diabetes mellitus than those with a normoglycaemic pregnancy, while an estimated four in 10 women in Singapore develop type 2 diabetes mellitus or pre-diabetes within four to six years of delivery.[2]
• Review Appropriate Care Guides around five years after publication, or earlier where new evidence requires substantive changes to recommendations.[5]
• Recognise that the guidance specifies clinical testing intervals and thresholds, but does not specify aggregate indicators, data collection arrangements, routine reporting channels, surveillance infrastructure, named accountable entities, audit procedures, targets, or sanctions for non-compliance.[2][4]

Costing & Financing

No explicit costing or financing framework is provided. The available material does not specify programme budgets, unit costs for glucose testing or follow-up, allocations to participating institutions, funding sources, resource-mobilisation plans, funding gaps, cost-effectiveness assumptions, or economic scenarios.[1][3][2][4]

• Identify the Agency for Care Effectiveness as a Ministry of Health-established body supporting healthcare decision-making through health technology assessments, healthcare guidance and education.[5]This institutional role does not include a stated budget, financing commitment, or resource allocation for implementation of this guidance.[1][3][2][4]
• Involve clinicians and expert-group members from Singapore healthcare institutions, including KK Women's and Children's Hospital, National University Health System, Singapore General Hospital, Tan Tock Seng Hospital and Khoo Teck Puat Hospital.[4]The material does not indicate whether these institutions receive dedicated funding, additional workforce, laboratory capacity, information-system support, or reimbursement for screening and long-term surveillance.[1][3][2][4]
• Recommend repeated oral glucose tolerance testing during pregnancy, at six to 12 weeks post-delivery, and thereafter at one- to three-year intervals for eligible women.[3][2][4]No associated test price, patient charge, provider payment mechanism, or estimate of total implementation cost is specified.[1][3][2][4]
• Recommend lifestyle intervention, glucose monitoring, specialist diabetes management and possible pharmacotherapy for relevant women.[2][4]The source does not quantify the financial, staffing, training, medicines, equipment, or service-delivery resources required for these measures.[1][3][2][4]
• Report that lifestyle intervention has been associated with a 35% reduction in progression from pre-diabetes to type 2 diabetes mellitus over 10 years.[2]This is an outcome estimate rather than a stated economic assumption, cost saving, budget impact, or cost-effectiveness result.[1][3][2][4]